Fund moves

Quest Diagnostics (DGX): Copeland Capital Management, LLC reduced its stake -3,044 shares

Copeland Capital Management, LLC reduced its stake in Quest Diagnostics, per its Q1 2025 13F.

196K
Shares reported · -3,044 vs prior quarter
0.67%
Disclosed portfolio weight
$33.2M
Reported value
Holdings as of
Mar 31, 2025
Filed
Apr 24, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 27, 2025Insider · 2 peopleInsiders: 2 sales (~$233K)
  2. Mar 4, 2025Insider · 2 peopleInsiders: 2 sales (~$230K)
  3. Mar 5, 2025InsiderOfficer sold ~$935K of DGX shares in the open market
  4. Mar 10, 2025CongressDisclosed sale of DGX — reported range $1,001 - $15,000
  5. Mar 17, 2025InsiderOfficer sold ~$789K of DGX shares in the open market
  6. Apr 2, 2025Insider · 2 peopleInsiders: 16 sales (~$7.0M)

What came next

  1. May 12, 2025InsiderOfficer sold ~$154K of DGX shares in the open market
  2. May 13, 2025InsiderOfficer sold ~$153K of DGX shares in the open market
  3. Jul 24, 2025FDAFDA device approval: Quest Diagnostics AAVrh74 Antibody ELISA CDx
  4. Jul 30, 2025Insider · 1 personInsiders: 2 sales (~$1.4M)
  5. Jul 31, 2025InsiderOfficer sold ~$376K of DGX shares in the open market
  6. Aug 6, 2025Insider · 1 personInsiders: 2 sales (~$969K)
  7. Aug 15, 2025InsiderOfficer sold ~$356K of DGX shares in the open market
  8. Aug 19, 2025InsiderOfficer sold ~$829K of DGX shares in the open market
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Quest Diagnostics

For Quest Diagnostics, OQRO holds 20 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DGX page.

How this filing works

Explore the data

Common questions

What does this filing report about Quest Diagnostics (DGX) stock?

Copeland Capital Management, LLC reduced its stake in Quest Diagnostics, per its Q1 2025 13F. Now 196K shares, $33.2M reported value, 0.67% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2025. Filed: Apr 24, 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Quest Diagnostics recently?

For Quest Diagnostics, OQRO holds 20 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the DGX page.

Does this mean DGX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Quest Diagnostics

Everything OQRO holds on this company is on its DGX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data